Marvel Biosciences (TSXV:MRVL) Tax Provision : C$0.00 Mil (TTM As of Oct. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Marvel Biosciences Tax Provision?

Marvel Biosciences's tax provision for the three months ended in Oct. 2024 was C$0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Oct. 2024 was C$0.00 Mil.

Marvel Biosciences Tax Provision Historical Data

The historical data trend for Marvel Biosciences's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marvel Biosciences Tax Provision Chart

Marvel Biosciences Annual Data

Trend

Jul20

Jul21

Jul22

Jul23

Jul24

Tax Provision

Marvel Biosciences Quarterly Data
	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24
Tax Provision	Get a 7-Day Free Trial													-	-	-	-	-

Marvel Biosciences Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Oct. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

Marvel Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (TSXV:MRVL) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

MBCOF:USA

Address

505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2

Website

https://www.marvelbiotechnology.com

Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

Executives